{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-242808","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.715511+00:00","generated_at":"2026-05-30T10:36:26.588263+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lyell to acquire ImmPACT Bio for $30M cash + 37.5M shares; discontinues LYL797, LYL845","bullets":["Upfront consideration: $30M cash (adjusted for ImmPACT's ~$16M cash) and 37.5M Lyell shares.","Contingent consideration: up to 12.5M additional shares on clinical/regulatory milestone + low single-digit US royalty on IMPT-314.","Pipeline prioritization: discontinuation of LYL797 (ROR1 CAR T), LYL845 (TIL), and preclinical TIL programs.","Focus on IMPT-314 (dual CD19/20 CAR T) and LYL119 (next-gen ROR1 CAR T); pivotal trial for IMPT-314 expected 2025.","Cash runway post-close into 2027; transaction expected to close Q4 2024 subject to HSR clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-242808","json":"https://secwatch.observer/filing/0001193125-24-242808.json","markdown":"https://secwatch.observer/filing/0001193125-24-242808.md","text":"https://secwatch.observer/filing/0001193125-24-242808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524242808/0001193125-24-242808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524242808/d881076d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:36:26.588263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}